文献速递膀胱癌与上尿路尿路上皮癌

全身炎症标志物与高危非肌层浸润性尿路上皮膀胱癌患者的肿瘤学结局

Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2018-07-13

研究纳入2002年1月1日至2012年12月31日期间在13家学术机构接受首次经尿道膀胱肿瘤电切术的1151例非肌层浸润性膀胱癌患者,中位随访48个月,评估中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和淋巴细胞/单核细胞比值组合的预后价值。结果显示全身炎症标志物评分越高,无复发生存率和无进展生存率越低,复发和进展风险越高。作者认为高评分的高级别T1期患者肿瘤学结局更差,需进一步研究以根据评分筛选可能从早期膀胱切除术获益的患者。

要点

  • 全身炎症标志物评分基于中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和淋巴细胞/单核细胞比值计算。
  • 评分0、1、2、3分的48个月无复发生存率分别为80.8%、47.35%、20.67%、17.06%(p<0.01)。
  • 评分1、2、3分与复发的风险比分别为3.73、7.06、7.88,与进展的风险比分别为3.15、4.41、5.83。

核心结论

  • 高全身炎症标志物评分的高级别T1期非肌层浸润性膀胱癌患者复发和进展的肿瘤学结局更差。
  • 作者认为需进一步研究以根据全身炎症标志物评分对患者进行分层,识别可能从早期膀胱切除术获益的个体。

研究设计与样本

  • 多中心分析,纳入2002年1月1日至2012年12月31日在13家学术机构接受首次经尿道膀胱肿瘤电切术的1151例非肌层浸润性膀胱癌患者,中位随访48个月。
  • 干预为经尿道膀胱肿瘤电切术联合膀胱内化疗或免疫治疗。
  • 采用多变量Cox回归分析识别复发、进展、癌症特异性死亡和总死亡的预测因素,并基于中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值和淋巴细胞/单核细胞比值的截断值计算全身炎症标志物评分。

主要发现

  • 全身炎症标志物评分0、1、2、3分患者的48个月无复发生存率分别为80.8%、47.35%、20.67%、17.06%(p<0.01,对数秩检验)。
  • 全身炎症标志物评分0、1、2、3分患者的48个月无进展生存率分别为92.0%、75.67%、72.85%、63.1%(p<0.01,对数秩检验)。
  • 全身炎症标志物评分1、2、3分与复发相关(风险比分别为3.73、7.06、7.88)。
  • 全身炎症标志物评分1、2、3分与进展相关(风险比分别为3.15、4.41、5.83)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 缺乏外部验证。
  • 缺乏与其他临床风险模型的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum levels of neutrophils, platelets, and lymphocytes have been recognized as factors related to poor prognosis for many solid tumors, including bladder cancer (BC). OBJECTIVE: To evaluate the prognostic role of the combination of the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and lymphocyte/monocyte ratio (LMR) in patients with high-risk non-muscle-invasive urothelial BC (NIMBC). DESIGN, SETTING, AND PARTICIPANTS: A total of 1151 NMIBC patients who underwent first transurethral resection of the bladder tumor (TURBT) at 13 academic institutions between January 1, 2002 and December 31, 2012 were included in this analysis. The median follow-up was 48 mo. INTERVENTION: TURBT with intravesical chemotherapy or immunotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regression analysis was performed to identify factors predictive of recurrence, progression, cancer-specific mortality, and overall mortality. A systemic inflammatory marker (SIM) score was calculated based on cutoffs for NLR, PLR, and LMR. RESULTS AND LIMITATIONS: The 48-mo recurrence-free survival was 80.8%, 47.35%, 20.67%, and 17.06% for patients with an SIM score of 0, 1, 2, and 3, respectively (p<0.01, log-rank test) while the corresponding 48-mo progression free-survival was 92.0%, 75.67%, 72.85%, and 63.1% (p<0.01, log-rank test). SIM scores of 1, 2, and 3 were associated with recurrence (hazard ratio [HR] 3.73, 7.06, and 7.88) and progression (HR 3.15, 4.41, and 5.83). Limitations include the lack of external validation and comparison to other clinical risk models. CONCLUSIONS: Patients with high-grade T1 stage NMIBC with high SIM scores have worse oncologic outcomes in terms of recurrence and progression. Further studies should be conducted to stratify patients according to SIM scores to identify individuals who might benefit from early cystectomy. PATIENT SUMMARY: In this study, we defined a risk score (the SIM score) based on the measurement of routine systemic inflammatory markers. This score can identify patients with high-grade bladder cancer not invading the muscular layer who are more likely to suffer from tumor recurrence and progression. Therefore, the score could be used to select patients who might benefit from early bladder removal.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Cantiello F, Russo GI, Vartolomei MD, et al. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2018. PMID: 31158079. doi:10.1016/j.euo.2018.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。